Coming off of a fiscal year whereby revenues jumped by more than 1,400%, the recent 3 month period finally has traders paying attention to the penny stock of Oncologix Tech, Inc. (OCLG). Bursting revenues from one acquisition made and hints of another one to come with even bigger sales attached to it, shares of OCLG stock have returned to where they were when the Company acquired Esteemcare Inc. If only the debt could be better managed, this is one healthcare driven company that could run like it stole something.
Want to crush the Markets and make profits of $624, $2,897, even $40,656?
Click HERE To Make Sure You Get All Of Our Penny Stock Alerts!
OCLG Stock Quote
|Close||0.0057||Change (% Chg)||+0.0015 (+35.71%)|
|14-Day Rel Strength||68.80%||Market Cap||$967.75K|
|52Wk High||0.0274||52Wk Low||0.0024|
Oncologix Tech, Inc. has a mission that appears to be being executed effectively – to be the best small-cap medical device and services holding company. Prior to the opening bell on Friday, the Company filed their Q for the three months ended November 30, 2014 which was highlighted by revenues of $1,161,874, more than $400,000 better than the $724,632 the Company reported for the same period in 2013.
On September 25, 2014, Oncologix Tech acquired the outstanding stock of Esteemcare, Inc. and it’s wholly owned subsidiary Affordable Medical Equipment Solutions, Inc. This deal immediately made OCLG stock a track-able ticker since Esteemcare is an accredited durable and home medical equipment and supply distributor for respiratory therapy, targeting patients with sleep obstructive disorders or related chronic illnesses who are insured by Medicare, Medicaid, third-party insurers, or have the ability to pay for our products from their own private resources.
Proof that sleep apnea is a serious sleep disorder that occurs when a person’s breathing is interrupted during sleep was evidenced in their annual report for the year ended August 31, 2014 whereby revenues came in at a whopping $3,677,475, more than 14X the $244,246 that was booked during the prior fiscal year. The market for people with untreated sleep apnea stop breathing repeatedly during their sleep, sometimes hundreds of times, which cuts deprives oxygen to the brain and the rest of the body would seem to be limitless or at least the adult population of the U.S.
Actually, $5.0 trillion is what U.S. domestic healthcare spending is expected to grow to in 2022, according to the Centers for Medicare and Medicaid Services. The niche portion of that spending which is concentrated on Continuous Positive Airwave Pressure (CPAP) Therapy to treat sleep disorders is projected to grow at 15%-20% for the next 5 years – the largest growing product line in healthcare.
How it works is pretty simple – a mask is worn over the nose and/or mouth while you sleep. The mask is hooked up to a machine that delivers a continuous flow of air into the nose which helps keep the airways open so that breathing is regular. CPAP is considered by many experts to be the most effective treatment for sleep apnea.
What Are the Effects of Sleep Apnea?
If left untreated, sleep apnea can result in a growing number of health problems, including:
• High blood pressure
• Heart failure, irregular heart-beats, and heart attacks
• Worsening of ADHD
So why has OCLG stock been so riddled with declines over the last 6 months until now?
The simple answer is convertible notes payable as evidenced in any recent filing you research for Oncologix Tech. Just glancing at their 10-K shows that notes payable grew to $1,028,636 for the year ended August 31, 2014 compared to the $138,494 that was on the books a year prior. Further to that, there were 76,036,894 unregistered shares of OCLG stock between October, 2012 and August, 2014 for a mere $116,000, an average of roughly $0.0015 with the last one being 1,200,000 shares to an affiliated accredited investor at $0.00833 per share.
A year ago, the Company secured a $4 million line of credit with TCA Global Credit Master Fund LP which allowed for them to have access to the $500,000 needed to buy Esteemcare from Madhu Mathew Mammen and Imad Siddiqui in September. While Ocologix did note in December that they were reducing this dilution as much as possible by by repaying initial installment in lieu of issuance of common stock shares, it took a Q filing on Friday for traders to finally be convinced that OCLG had some real potential to run.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About OCLG Stock
Oncologix Tech, Inc. is a diversified medical holding company with operating segments in medical device, healthcare services and medical products and technologies.
Issued and Outstanding: 169,780,297
Last 5 Trading Sessions:
As beaten down as OCLG has been over the last 6 months, and the fact that its a multi-million dollar revenue generator with hints of becoming even bigger, the chances of seeing this become one of the hottest sub-penny stocks heading into February just got increased. Although TCA Global isn’t a guaranteed lock for a run to occur, being that there have been runners they’ve backed before makes sleeping on OCLG this week an act that could cost you plenty more than the rest you get. Two consecutive days of record -breaking volume is indicative that the smart money is already in and has their laces tied on tight for what’s about to come.
[gravityform id=”6″ name=”Post” title=”false”]
We are 100% Anti-Spam and will never rent or sell your information.
Many of our picks go up 100%, 200%, even 10,000%, see for yourself.
OCLG,OCLG Stock,OCLG Scam,OCLG Stock Quote, OCLG Report,OCLG Shares,Oncologix Tech Inc.,Oncologix Tech,hot healthcare stocks,Hot Penny Stock Alerts,Hot Penny Stock,hot penny stocks, hot OTC stocks, best OTC stocks, best penny stocks,Best Penny Stocks to Buy,penny stocks to watch, penny stock picks, penny stocks to buy, otc stocks, penny stock trading, penny stocks list, good penny stocks,top 10 penny stocksShare